Compare SHOE & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOE | CUVL |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Clothing/Shoe/Accessory Stores | Miscellaneous |
| Sector | Consumer Discretionary | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.5M | 374.2M |
| IPO Year | 1994 | N/A |
| Metric | SHOE | CUVL |
|---|---|---|
| Price | $14.07 | $6.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 665.8K | 13.8K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,135,324,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.78 | $5.95 |
| 52 Week High | $16.29 | $8.20 |
| Indicator | SHOE | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 42.75 |
| Support Level | N/A | $6.33 |
| Resistance Level | $16.01 | $6.82 |
| Average True Range (ATR) | 0.60 | 0.43 |
| MACD | -0.20 | -0.10 |
| Stochastic Oscillator | 25.12 | 18.89 |
Shoe Station Group Inc is a one-stop family footwear destination that offers an impressive selection from top brands. It is a fashion destination for footwear, southern-inspired accessories, and apparel. The group has physical stores throughout five Southern states and is available online at ShoeStation.com, shipping all across the U.S. Its offer products for Women's, Men's, and Kids.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.